Lucentis Efficacy and Safety in DME
Statement in response to topline results from Protocol-T study
Novartis is aware that the topline results of the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol T, a head-to-head open label study conducted in the US comparing Lucentis 0.3 mg (ranibizumab), Eylea 2 mg (aflibercept) and unlicensed intravitreal Avastin 1.25 mg (bevacizumab) for the treatment of visual impairment due to diabetic macular edema, (DME) were shared.
As demonstrated through studies involving more than 1300 patients included in 4 pivotal trials RESTORE, RESOLVE, RIDE and RISE, plus one DRCR.net study, Lucentis is an efficacious treatment for DME patients, providing rapid, significant and sustained vision gains for more than 3 years with decreasing injection frequency.
Lucentis has a well-characterized safety profile, with more than 2.8 million patient-treatment years of exposure globally. The well-established safety profile is supported by extensive clinical trial data and real-world experience.
Lucentis, licensed since 2011 for DME, is approved in more than 100 countries for DME. Lucentis has demonstrated transformational efficacy in the treatment of visual impairment in patients with DME, wet age-related macular degeneration (wet AMD), branch retinal vein occlusion (BRVO), central RVO (CRVO) and myopic choroidal neovascularization (myopic CNV).
Novartis awaits publication of the full results and further analysis of the data.